The role of sphingosine-1-phosphate (S1P) and its receptors in the pathogenesis of atherosclerosis has not been investigated.
S phingosine-1-phosphate (S1P) is a bioactive lipid with key functions in the immune, inflammatory, and cardiovascular systems. S1P is abundant in plasma (200 to 1000 nmol/L 1,2 ), where it is contained mainly in the high-density lipoprotein fraction 3 in a biologically active form. 4 Accordingly, plasma S1P levels correlate positively with plasma high-density lipoprotein cholesterol and apolipoprotein AI. 2 As a component of both plasma and interstitial fluid, S1P interacts with all vascular and nonvascular cell types that participate in the pathogenesis of atherosclerosis. All these cells have functional S1P receptors and respond to S1P in a number of different ways, 5 which has prompted the question whether S1P and its receptors may play a role in the pathogenesis of atherosclerosis. A positive association between serum S1P levels and the severity of coronary artery stenosis has been described in humans. 6 The effect of the S1P analog FTY720 on mouse atherosclerosis has been elucidated in 3 independent studies including one from our group. Two of these studies have shown FTY720 to attenuate the development of atherosclerosis in apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) 7 and LDL-receptor deficient (LDL-R Ϫ/Ϫ ) mice, 8 respectively, whereas the third observed no effect on plaque size. 9 Mechanistically, FTY720 does not allow discriminating between the roles of individual S1P receptors as it engages 4 of 5 S1P receptors and exhibits different receptor desensitization kinetics from S1P. 10 The mechanism of how FTY720 inhibits atherosclerosis has also remained unknown in view of the variety of its potentially atheroprotective effects: it stimulates nitric oxide production in endothelial cells, 11 inhibits the production of reactive oxygen species and chemokines such as monocyte chemoattractant protein (MCP)-1, 12 alters the production of inflammatory cytokines, 8 and acts as a potent immunosuppressant. 13 As the S1P receptor 3 (S1P 3 ) appears to contribute to several of these effects, we directly addressed its role in atherosclerosis and inflammation in the present study. For this, we have examined atherosclerotic lesion development in S1P 3 Ϫ/Ϫ / ApoE Ϫ/Ϫ double knockout mice as well as in bone marrow chimeras, and studied the recruitment of inflammatory monocyte/ macrophages during thioglycollate-induced sterile peritonitis in S1P 3 Ϫ/Ϫ mice. Our study provides in vitro and in vivo evidence that the S1P 3 receptor on monocyte/macrophages affects their migration properties and inflammatory potential and promotes their recruitment to inflammation sites and atherosclerotic lesions.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice

S1P 3
Ϫ/Ϫ mice were crossbred to the C57BL/6 background for more than 10 generations and subsequently to ApoE Ϫ/Ϫ . FTY720 was administered orally at 1.25 mg/kg per day. 7
Hematology and Flow Cytometry
Total and differential white blood cell counts were measured in EDTA-blood from the retroorbital plexus using an automated Animal ABC Coulter Counter. Flow cytometry of blood, bone marrow and peritoneal exudate was performed with fluorochrome-conjugated antibodies to CD4, CD8, CD45, B220, Gr-1, I-A b , Ly-6G, F4/80, CD11b, and CD115 on a FC500 flow cytometer.
Immunohistochemistry
Immunohistochemistry was performed on adjacent sections with antibodies to ␣SMA, Mac-2 and sphingosine kinase (Sphk)1 (a kind gift from Dr Lina Obeid, Medical University of South Carolina). Collagen content was assessed by picrosirius red staining and polarized light. Immunostaining for every marker was performed in a single procedure. Automated color segmentation of images was performed, and a color threshold of chromogen stain defined using a negative isotype-matched control antibodies. The area containing all positive pixels was expressed as percentage of total plaque area.
Flow Cytometry of Single Aortae
Single-cell suspensions from aortae were prepared following a protocol graciously provided by Prof Klaus Ley (Division of Inflammation Biology, La Jolla Institute for Allergy & Immunology), as described 14 with minor modifications. Briefly, mice were perfused with 0.02 mol/L EDTA and the carefully dissected aorta cut into small pieces and digested in an enzyme cocktail. Cells were stained with CD45-PE-Cy7, CD11b-APC (clone M1/70 or Mac-1) and I-A b -PE as described. 14 Annexin-V-FITC served to differentiate living from apoptotic cells. Cells negative for Annexin-V were back-gated to CD45 and examined for CD11b and I-A b . Percentages and total numbers were determined from the entire cell suspension of each aorta.
Isolation of Peritoneal and Bone Marrow Macrophages, Migration Studies, and S1P Measurements
Peritoneal exudate and macrophages were collected after intraperitoneal injection of aged sterile 3% thioglycollate at the indicated times. Bone marrow-derived macrophages (BMDMs) were generated by culture of bone marrow cells with 1.5 ng/mL M-CSF for 10 days. Migration of thioglycollate-elicited peritoneal macrophages (day 4) toward 1 mol/L S1P was measured in a modified Boyden chamber after 4 hours and quantified from at least 3 experiments performed in triplicate. MCP-1 was measured using an ElisArray mouse MCP-1. Determination of S1P was performed by HPLC as previously published. 15
Quantitative PCR
Total RNA was isolated and cDNA synthesized using RNeasy Mini Kit and Revert Aid First Strand cDNA Synthesis Kit, respectively. Realtime PCR was performed on a Bio-Rad iCycler using iQ SYBR Green and Quantitect primers. The absolute copy number of S1P 1 , S1P 2 , and S1P 3 was expressed as copies per 1000 copies GAPDH [gene (normalized)ϭcopy number of target/copy number of reference] from standard concentration curves for each gene transcript. Relative quantification of gene expression was calculated by the 2 Ϫ⌬⌬CT method.
Bone Marrow Transplantation
Mice were irradiated with 11 Gy (x-rays) and transplanted with 5ϫ10 6 donor bone marrow cells via retroorbital injection the following day.
Quantification of Lesions
En face staining of PFA-fixed aortae was performed with 0.3% oil red O for 90 minutes. Lipid-containing stained plaque area was determined as percent from total aortic surface area using the AxioVision 4.6 software. Quantification of atherosclerotic lesion volume in the brachiocephalic artery (BCA) and aortic root was performed as described. 16 Briefly, the entire BCA was serially sectioned in 5 m sections and, from a random start site within the first 75 m, every 15th section was stained with H&E and the volume of the lesion determined using the Cavalieri stereologic method [⌺(lesion area)ϫ(distance; 75 m)]. 16 
Carotid Ligation, Smooth Muscle Cell Proliferation, and Migration
The left carotid artery was ligated at the bifurcation as previously described 17 and serially sectioned over its entire length 4 weeks after surgery. Every 10th section starting at the ligation site was stained with H&E and neointimal and medial areas and neointimal cells were quantified by histomorphometry. Smooth muscle cells (SMCs) were isolated from aortae (6 to 7 aortae per preparation) by enzymatic digestion as described, 17 plated on Vitrogen100, and used for experiments up to the sixth passage. For proliferation studies, SMCs were serum-starved for 24 hours and cultured in 1% FCS in the presence or absence of 1 mol/L S1P and 1 nmol/L platelet-derived growth factor (PDGF), respectively, added every other day for 4 days TNF tumor necrosis factor as described. 18 Total cell numbers were determined using a Z2 cell counter. All experiments were performed in triplicate. For migration studies, cells were starved for 24 hours and seeded in DMEM with 0.25% BSA at a density of 10 000 per well on Vitrogen100-coated membranes in the upper well of a modified Boyden chamber. Migration to 1 mol/L S1P, 1 nmol/L PDGF and both, respectively, was assessed after 4 hours by counting the cells migrated to the lower side of the membrane in one field of view at 10x magnification as described. 18 Five independent experiments in triplicate were performed.
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Statistical Analysis
Each experiment was performed at least 3 times as indicated, and data presented as meansϮSEM. Statistical significance was evaluated by a nonparametric Wilcoxon-Mann-Whitney U test. Two-sided probability values of less than 0.05 were considered significant.
Results
S1P 3 Deficiency Has No Effect on Atherosclerotic Lesion Volume but Dramatically Reduces Monocyte/Macrophage Content in Atherosclerotic Lesions of S1P 3
؊/؊
/ApoE ؊/؊ Mice
To analyze the effect of S1P 3 deficiency on atherosclerotic lesion formation, we backcrossed S1P 3 knockout mice to the C57BL/6 background for 10 generations and crossbred them with ApoE Ϫ/Ϫ deficient mice. We then compared size and composition of atherosclerotic lesions in the aorta and the brachiocephalic artery (BCA), respectively, of S1P 3 Ϫ/Ϫ / ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ mice fed a standard chow diet for 25 and 45 weeks, respectively. Neither lipid accumulation in the aorta (determined en face using oil red O) nor lesion volume (determined by the Cavalieri method in the BCA) was different between S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ mice (Figure 1 ). In contrast, the monocyte/macrophage content and the SMC con-tent of the lesions differed dramatically: macrophage content was reduced by 76% in S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ compared to ApoE Ϫ/Ϫ (6.63Ϯ1.05% versus 27.34Ϯ2.65%), whereas SMC content was increased by 74% in S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ compared to ApoE Ϫ/Ϫ (7.29Ϯ0.95% versus 4.24Ϯ0.60%; Figure 2A and 2B). The collagen content did not differ significantly between the 2 groups (9.61Ϯ1.37% versus 8.28Ϯ1.07%; Figure 2 ). Necrotic core area was larger in S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ than in ApoE Ϫ/Ϫ (42.54Ϯ17.4 versus 25.09Ϯ12.1; PϽ0.05) in advanced plaques of similar size (median, 127 147 m 2 ; range, 38 984 to 210 522, nϭ16; versus median, 105 665 m 2 ; range, 58 101 to 243 596, nϭ22) and necrotic core larger than 10 000 m 2 .
Using flow cytometry of single digested aortae with antibodies to CD45, CD11b, and I-A b as described, 10, 14, 19 we observed a lower percentage of CD45 ϩ CD11b ϩ I-A bϩ macrophages in S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ aortae compared to ApoE Ϫ/Ϫ aortae (45.7Ϯ2.6% versus 55.6Ϯ2.6%; Figure 2C and 2D). Total macrophage cell number per individual aorta was also lower in S1P 3
Ϫ/Ϫ /ApoE Ϫ/Ϫ mice compared to ApoE Ϫ/Ϫ (628Ϯ153 versus 1494Ϯ225; Figure 2E ). Thus, macrophages were clearly reduced in the aortae of S1P 3
In contrast, no differences in total monocytes, neutrophils, or monocyte subsets (CD115 ϩ F4/80 ϩ Gr-1 low and CD115 ϩ F4/80 ϩ Gr-1 high ) were present in the peripheral blood ( Figure 3 
S1P 3 Deficiency Attenuates Macrophage Recruitment During Thioglycollate-Induced Sterile Peritonitis
We hypothesized that a defect in macrophage recruitment per se may be caused by the absence of S1P 3 and underlie the reduced macrophage content of atherosclerotic lesions of S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice. To test this, we used the thioglycollate-induced peritonitis model as a classical model to study macrophage-driven sterile inflammation ( Figure 4A ). In this model, we observed a dramatic reduction in the peritoneal numbers of F4/80 ϩ Gr-1 Ϫ macrophages in S1P 3deficient mice compared to controls 48 and 96 hours, respectively, after initiation of peritonitis ( Figure 5A and 5B; Online Figure II ). In contrast, the influx of neutrophils measured at day 1 was not different between the 2 genotypes (9.15Ϯ2.99 versus 7.45Ϯ1.84ϫ10 6 /mouse).
We then compared the expression of the S1P 1 , S1P 2 , and S1P 3 receptors both in thioglycollate-elicited peritoneal macrophages and BMDMs by real-time PCR ( Figure 4B and 4C). In both macrophage types, expression of S1P 1 and S1P 2 was 2 to 3-fold higher than that of S1P 3 (determined as absolute copies of gene transcript per 1000 copies GAPDH; Figure  4B ). Gene transcript number was comparable between peritoneal and BMDMs for all 3 S1P receptors ( Figure 4C ).
S1P 3 -Deficient Macrophages Exhibit an Altered Cytokine Expression Profile Compared With Controls
We then tested for alterations in the expression of inflammatory chemokines, cytokines, and cytokine receptors in S1P 3 Ϫ/Ϫ peritoneal macrophages by real-time PCR. We found MCP-1 and tumor necrosis factor (TNF)␣ gene expression to be reduced by 70% to 80% in S1P 3 Ϫ/Ϫ macrophages ( Figure 5C ), whereas other genes were unchanged at the mRNA (interleukin [IL]-4, IL-6, IL-10, IL-1␣, MIP-1␣, GM-CSF, CCR2; Figure 5C ) or protein level (iNOS, arginase-1, CCR2, CCR7, CX3CR1, and CD80; data not shown). In agreement, protein levels of MCP-1 were reduced more than 150-fold in the peritoneal exudates of S1P 3 Ϫ/Ϫ mice compared to controls as measured by ELISA ( Figure 5C , inset). Incubation of BMDMs with S1P did not have any effect on basal or lipopolysaccharide (LPS)-stimulated MCP-1 expression in wild-type or S1P 3 Ϫ/Ϫ macrophages (Figure 5D ). However, the extent of MCP-1 induction by LPS was attenuated in S1P 3 Ϫ/Ϫ macrophages compared to controls ( 
S1P Levels Increase in the Inflamed Peritoneum In Vivo; S1P Chemoattracts Macrophages via S1P 3 In Vitro; FTY720 Abolishes Peritoneal Macrophage Recruitment In Vivo
We measured S1P levels in the peritoneal exudate by HPLC at different times after induction of inflammation as described 15 and observed a time-dependent increase of S1P concentrations in the peritoneal fluid with a maximum at 24 hours and a subsequent decrease ( Figure 6A ). We hypothesized that such an S1P increase might be biologically important and tested it in 2 ways. Firstly, we examined whether S1P may be a chemoattractant for thioglycollate-elicited peritoneal macrophages in vitro. This was, indeed, the case as wild-type macrophages migrated toward a 1 mol/L S1P gradient in Boyden chamber experiments ( Figure 6B ). In contrast, S1P 3 Ϫ/Ϫ macrophages did not migrate toward S1P ( Figure 6B ), suggesting that S1P 3 is responsible for mediating the chemotactic response to S1P. Secondly, we eliminated any biological effects that S1P gradients may have in vivo by treating mice with the S1P analog FTY720 as previously described for lymphocytes. 20 This resulted in a Ϸ80% reduction in the number of elicited macrophages after thioglycollate application ( Figure 6C ), suggesting that S1P gradients may be required for effective monocyte/macrophage recruitment to the inflamed peritoneum in vivo.
Sphingosine Kinase 1 Is Expressed in Lesions of Atherosclerosis
Immunohistochemistry for Sphk1 of atherosclerotic lesions of ApoE Ϫ/Ϫ mice showed that the enzyme was abundantly expressed there and colocalized mainly with macrophages ( Figure 6D ). This suggested that S1P-synthesizing enzymes such as Sphk1 may promote local production of S1P in atherosclerotic lesions.
S1P 3 in Both Hematopoietic and Nonhematopoietic Cells Is Required for Monocyte/Macrophage Accumulation in Atherosclerotic Lesions
To examine the role of the monocyte/macrophage S1P 3 in the recruitment of inflammatory cells to atherosclerotic lesions, we generated bone marrow chimeras by reconstituting the bone marrow of sublethally irradiated ApoE Ϫ/Ϫ mice with that of S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice and vice versa. Successful bone marrow substitution was verified by diagnostic PCR for the deleted and wild-type S1P 3 allele on genomic DNA from total blood of S1P 3 Figure 7A ). Lesion size did not differ significantly between the chimeras after 25 weeks but their monocyte/macrophage content was reduced by Ϸ26% in the S1P 3 Ϫ/Ϫ / ApoE Ϫ/Ϫ 3 ApoE Ϫ/Ϫ bone marrow chimeras compared to the ApoE Ϫ/Ϫ 3 S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ chimeras (26.25Ϯ2.03% versus 19.51Ϯ1.59%; Figure 7B and 7C). This suggested that expression of S1P 3 in monocyte/macrophages partially contributes to their accumulation in atherosclerotic lesions. Analysis of the SMC content of the same lesions showed it was increased in the S1P 3
89Ϯ0.93% versus 3.10Ϯ0.26%; Figure 7D ).
Neointima Formation After Carotid Ligation Is Increased in S1P 3 ؊/؊ Mice
To follow up on the finding of an elevated SMC content in atherosclerotic lesions of S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice, we used the carotid artery ligation model. 21, 22 There, we observed a larger neointima formation in S1P 3 Ϫ/Ϫ mice compared to C57BL/6 controls over the entire length of the ligated carotid (Figure 8) . To test the behavior of S1P 3 -deficient SMCs in vitro, we isolated adult aortic SMCs from both genotypes and measured their migration and proliferation properties in response to S1P, PDGF-BB and both. S1P potently inhibited basal and PDGF-BB-induced SMC migration as published 18 and was equally effective in wild-type and S1P 3 Ϫ/Ϫ SMCs ( Figure 8C ). Proliferation in response to PDGF-BB was similar in SMCs from both genotypes and was unaffected by S1P ( Figure 8D ).
Discussion
Our study is the first to address the role of S1P 3 in the pathogenesis of atherosclerosis in vivo. Our initial observation was that macrophage content was decreased in atherosclerotic lesions of S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ double knockout mice. Using bone marrow chimeras, we could partially attribute this to the lack of S1P 3 in hematopoietic cells. A possible scenario how this may occur is that monocyte/macrophages are chemoattracted toward an increased S1P level inside the lesion, to which they respond via their S1P 3 receptor. This resembles the action of the bone fide chemokines in atherosclerosis. Several of our observations support such a scenario: S1P was chemotactic for macrophages in vitro; migration to S1P was dependent on the macrophage S1P 3 receptor in vitro, and S1P 3 -deficient mice recruited less monocyte/macrophages in the peritonitis model. During peritonitis, S1P levels increased locally in the inflamed peritoneum, thereby providing a Figure 4 . Quantification of S1P 1 , S1P 2 , and S1P 3 gene expression in peritoneal and BMDMs. A, Schematic of thioglycollate-induced peritonitis. B, Quantitative assessment of S1P receptor expression was performed in thioglycollate-elicited peritoneal macrophages (4 days after injection) and BMDMs from control and S1P 3 Ϫ/Ϫ mice by real-time PCR. The absolute copy number of S1P 1 , S1P 2 , and S1P 3 is expressed per 1000 copies of GAPDH. *PϽ0.05 (expression of S1P 3 compared to S1P 1 and S1P 2 ). C, Representative PCR for S1P 1 , S1P 2 , and S1P 3 in peritoneal macrophages and BMDMs of control and S1P 3 Ϫ/Ϫ mice. GAPDH and ␤-actin served as endogenous controls. gradient along which macrophages might be recruited. Indeed, macrophage recruitment was attenuated when the S1P gradient or, better, its biological consequences were annihilated by overloading the system with excess FTY720. This occurred in a manner that resembles the inhibition of lymphocyte migration out of lymph nodes by FTY720. 23 In respect to atherosclerosis, FTY720 has been shown to reduce the macrophage content of atherosclerotic lesions of ApoE Ϫ/Ϫ mice. 16 Although we could not measure the S1P content of atherosclerotic lesions directly, we found an abundant expression of Sphk1, which was colocalized mainly with macrophages. It is known that Sphk1 expression can be induced in vitro by several cytokines such as TNF␣ and IL-1␤ 24 that are also present and active in atherosclerotic lesions in vivo. Furthermore, Sphk1 expression is increased in endothelial cells in models of acute lung injury induced by LPS or thrombin. 25 Thus activated macrophages as well as vascular cells such as the endothelium may be potential sources of S1P in the lesion (as well as in the inflamed peritoneum in analogy).
Our finding that S1P is chemotactic for thioglycollateelicited peritoneal macrophages in vitro is in agreement with its chemotactic effect in RAW264.7 monocytic cells as well as in mouse BMDMs. 26 However, there are also reports of S1P lacking a chemotactic effect in mouse BMDMs but inhibiting migration toward C5a and CXCL12. 27 Such differences may be attributable to the different tissue sources of the used macrophages, as well as their different activation and differentiation states. For instance, the S1P responsiveness of the thioglycollate-elicited inflammatory macrophages (used immediately after isolation for experiments as in our study) Figure 6 . Increased S1P levels in the inflamed peritoneum; effects of S1P and S1P 3 on macrophage migration in vitro; altered macrophage recruitment by FTY720 in vivo, and Sphk1 expression in atherosclerotic lesions. A, S1P levels are increased during inflammation in the peritoneal cavity. Peritoneal exudate was collected after thioglycollate injection at the indicated time points and the cell-free fraction was analyzed for S1P (nϭ4 to 13 per time point). *PϽ0.05. B, S1P is chemotactic for peritoneal macrophages via the S1P 3 receptor. Thioglycollate-elicited peritoneal macrophages (4 days after injection) were collected and migration toward 1 m S1P was assessed in a modified Boyden chamber. Migrated cells were quantified by counting 8 visual fields for each condition. Data are expressed as mean of 3 experiments performed in triplicate. *PϽ0.05. C, Pretreatment with FTY720 attenuates thioglycollate-induced macrophage recruitment to the peritoneal cavity. Total numbers of elicited macrophages were determined 4 days after thioglycollate injection in mice treated with (nϭ11) and without (nϭ12) FTY720. **PϽ0.01. D, Sphk1 is expressed in atherosclerotic lesions of ApoE Ϫ/Ϫ mice and colocalizes with macrophages. Representative adjacent sections of the aortic root were stained for Sphk1, macrophages (Mac-2), and SMCs (␣SMA).
Figure 7. Macrophage content is reduced and SMC content is increased in aortic root lesions of S1P 3
؊/؊ /ApoE ؊/؊ bone marrow chimeras. Bone marrow transplantation (BMT) was performed in sublethally irradiated 12-week-old ApoE Ϫ/Ϫ and S1P 3 Ϫ/Ϫ / ApoE Ϫ/Ϫ mice using bone marrow from S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ mice, respectively. A, Representative diagnostic PCR for the deleted and wild-type S1P 3 alleles on total blood genomic DNA of S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ (donor)3 ApoE Ϫ/Ϫ (recipient) BM chimeras and ApoE Ϫ/Ϫ (donor)3 S1P 3
Ϫ/Ϫ /ApoE Ϫ/Ϫ (recipient) BM chimeras at the time of euthanasia (25 weeks after BMT). B, Representative immunohistochemistry for macrophages (Mac-2) and SMCs (␣SMA), respectively. Magnification: ϫ40 and ϫ100 (inset). C, Quantitative assessment of macrophage content. D, SMC content as percent of lesion area 25 weeks after BMT (nϭ5 each). *PϽ0.05. may very well differ from that of BMDMs generated from hematopoietic precursors by long-term culture with M-CSF. 27 In addition, different S1P receptors have apparently different effects on monocyte/macrophage migration: S1P 2 -deficient mice have been shown to recruit more peritoneal macrophages in the same peritonitis model as used in our study, whereas BMDMs from S1P 2 Ϫ/Ϫ mice were irresponsive to the migration-inhibitory effect of S1P on C5a and CXCL12. 27 This has lead to the suggestion that plasma S1P restrains macrophages from immigrating to inflammatory sites via S1P 2 . 27 Another option may be that S1P 2 retains macrophages inside the lesion once they have immigrated (provided the S1P content of the lesion is, indeed, increased). Our data suggest that macrophages use their S1P 3 receptor to immigrate to such S1P-containing lesions. A scenario in which S1P 2 prevents and S1P 3 promotes monocyte/macrophage recruitment is reminiscent of the functional antagonism of 2 other S1P receptors, S1P 1 and S1P 2 , in endothelial cell migration. 28 The S1P 1 receptor does not appear to play a role at least in macrophage recruitment to the inflamed peritoneum as shown using S1P 1 hematopoietic chimeras 27 and supported by our own data in mice carrying a conditional deletion of S1P 1 in myeloid cells (S1P 1 LysMCre ; data not shown). Despite the somewhat macrophage-centric view we have adopted here, it must be clearly established that nonhematopoietic components also contribute to the altered monocyte/ macrophage recruitment in S1P 3 -deficient mice. The macrophage content of lesions in the hematopoietic chimeras lacking S1P 3 was significantly reduced but this reduction was modest compared to that in the global S1P 3 knockout without bone marrow transplantation. In addition, wild-type mice transplanted with S1P 3
Ϫ/Ϫ bone marrow and S1P 3 Ϫ/Ϫ mice transplanted with wild-type bone marrow, respectively, showed no difference in peritoneal monocyte/macrophage recruitment after thioglycollate injection (Online Figure III) , suggesting that S1P 3 in the hematopoietic and the nonhematopoietic compo-nents is equally important. Whether its lack in either one is also sufficient to alter recruitment cannot be deduced from the data as we have not excluded possible effect of irradiation and stromal repopulation on the peritoneal response.
The most probable nonhematopoietic component in question is the endothelium: it is constantly exposed to the plasma S1P pool and needs it for maintenance of regular barrier function and prevention of vascular leakage. 29 In addition, S1P and/or S1P 1 agonists have been shown to inhibit monocyte adhesion to TNF␣-activated endothelium 30, 31 as well as the recruitment of neutrophils to postischemic inflammation. 32 The exact mechanisms have not been elucidated as several adhesion molecules and chemokines are differently affected by S1P and respond differently to low versus high S1P concentrations. 4 However, there is also contrary evidence in favor of a proinflammatory role of S1P in the endothelium: Sphk1 is stimulated by inflammatory cytokines in endothelial cells and the S1P it generates stimulates COX-2 activity and PGE 2 release 24, 25 ; it also mediates TNF␣stimulated adhesion molecule expression and promotes neutrophil adhesion (for a comprehensive review, see elsewhere 4 ). Finally, the same cytokines that use S1P for the propagation of inflammation can also be restrained by the same S1P as taking place during inflammatory lung injury, where the initial increase in vascular permeability by LPS or PAR-1 is restored by their induction of S1P production. 24, 25 Thus, S1P appears to play a role both in the propagation and limitation of vascular inflammation. Therefore, any net effect S1P may have on monocyte/macrophage recruitment in vivo must be the result of simultaneous signaling by several S1P receptors on endothelial and inflammatory cells.
Finally, S1P signaling via the S1P 3 receptor not only affects macrophage migration but also their activation profile: Thioglycollate-elicited S1P 3 Ϫ/Ϫ peritoneal macrophages exhibited reduced TNF␣ and MCP-1 expression suggesting a proinflammatory role for S1P 3 . Previously, an antiinflamma- tory role for S1P 1 and a proinflammatory one for S1P 2 , respectively, have been suggested based on S1P effects observed in BMDMs stimulated with LPS/IFN-␥. 33 Although we did not see any S1P effects on basal or LPS/IFN-␥stimulated cytokine expression (neither in wild-type nor S1P 3 Ϫ/Ϫ BMDMs), we did observe a blunted MCP-1 response to LPS in S1P 3 Ϫ/Ϫ macrophages. Thus S1P receptor signaling may affect cytokine expression of macrophages even in the absence of exogenous S1P. This may not only influence monocyte/macrophage function but also indirectly, via MCP-1, their recruitment in vivo.
The elevated SMC content we have seen in lesions of S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice and the enhanced neointima formation after carotid ligation suggest that S1P 3 also affects SMC phenotype. Despite numerous studies on S1P receptors in SMCs in vitro, only 2 studies have examined their role in vivo. In these, administration of a S1P 1 /S1P 3 antagonist in rats inhibited neointima formation after balloon injury of the carotid 34 and neointima formation after carotid ligation was enhanced in S1P 2
Ϫ/Ϫ mice. 17 The potent inhibition of PDGF-BB-induced migration by S1P and its lack of effect on basal migration that we see in our study confirm previous in vitro reports. 18, 28, 35 The absent effect of S1P on proliferation has also been described before e. g. for human SMCs, 18 although an enhanced proliferation by S1P has also been described for rat SMCs, where an S1P 1 /S1P 3 inhibitor prevented it but did not alter basal proliferation. 34 Although our data exclude S1P 3 as being involved in these processes in vitro, they clearly argue for its importance in vivo. Thus, the in vivo mechanism behind the aberrant SMC behavior in the absence of S1P 3 will need to be addressed in future studies, which need to take into consideration the fact that SMCs from different vessels express different S1P receptors and regulate them differently after vascular injury. 18, 28, 35 Nevertheless, our carotid ligation data point to an antiproliferative/antimigratory role of S1P 3 on SMCs in the arterial injury response that may explain the shift toward the more SMC-rich plaque composition in S1P 3 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice. In summary, further studies are needed to dissect the role of S1P receptors on vascular endothelial, smooth muscle and hematopoietic cells in the context of atherosclerosis. This would help to design novel pharmacological approaches to atherosclerosis based on S1P agonists and antagonists.
Novelty and Significance
What Is Known?
• Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid that regulates vascular permeability and vessel tone, immunity, and inflammation. In plasma, S1P is contained mainly in the high-density lipoprotein fraction and its concentrations are elevated in patients with coronary artery disease. • S1P exerts many of its functions via 5 G protein-coupled receptors named S1P 1 to S1P 5 that are differentially expressed on vascular and hematopoietic cells. • The S1P analog FTY720 inhibits atherosclerosis in mice but this observation does not allow the discrimination between the roles of individual S1P receptors because FTY720 engages them all except S1P 2 . Whereas the S1P 2 receptor seems to promote atherogenesis, the role of S1P 3 in atherosclerosis is unknown.
What New Information Does This Article Contribute?
• We show that the size of atherosclerotic lesions is similar, but the monocyte/macrophage content is dramatically reduced in S1P 3deficient mice on the atherosclerosis-susceptible ApoE Ϫ/Ϫ background. Replacement of the bone marrow of ApoE Ϫ/Ϫ mice with S1P 3 -deficient bone marrow and vice versa demonstrates that S1P 3 in both hematopoietic and nonhematopoietic cells contributes to macrophage accumulation in atherosclerotic lesions. • S1P 3 deficiency leads to a reduction of inflammatory macrophage recruitment to the peritoneum. Macrophages deficient for S1P 3 have an altered expression of inflammatory cytokines and produce less MCP-1 in response to stimulation with bacterial lipopolysaccharide. • S1P induces macrophage migration in vitro via the S1P 3 receptor. In vivo, S1P concentrations increase rapidly in the peritoneal cavity during inflammation.
Studies with pharmacological S1P analogs in mice have suggested that excessive activation and/or desensitization of S1P receptors may suppress atherosclerosis but the receptors involved have not been identified. We report that the S1P receptor, S1P 3 , on both vascular and hematopoietic cells is required for monocyte/macrophage infiltration of atherosclerotic lesions, as well as their recruitment during peritoneal inflammation. We show that S1P 3 promotes migration of macrophages to S1P and alters their cytokine expression profile. In addition, S1P 3 prevents smooth muscle cell proliferation and migration in response to arterial injury. This suggests that a specific blockade of S1P 3 may be a new therapeutic option to suppress inflammation in atherosclerotic lesions.
